Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a biopharmaceutical company focused on therapeutics to treat chronic liver diseases, has had its buy rating reiterated by analysts at Needham after the company's participation in an American Association for the Study of Liver Diseases (AASLD) meeting. Analyst Alan Carr commented, "Intercept presented additional data relating to the Phase 3 OCA POISE trial in PBC and hosted an event with investors at the AASLD meeting. This follows publication of Phase 2 OCA FLINT trial results in NASH in Lancet last week. Data from the FLINT trial highlight a comprehensive benefit, including improvement in fibrosis regardless of severity at baseline. Although relevance of lipid changes is still unclear, we believe the drug is likely to emerge as an attractive option in NASH based on overall safety/efficacy profile and absence of any approved therapy for this large patient population." Over the past 52 weeks, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has traded between $48 and $497.Click here for a free comprehensive Trend Analysis ReportA notable analyst action consisted of UBS maintaining its Buy rating on Apple Inc. (NASDAQ:AAPL), the operating system and smartphone giant but nudged its price target to $125 from $115, citing China demand and brand strength. Said analyst Steven Milunovich: "About 40% of respondents are likely to buy an iPhone 6 in the next year. Over half of intended purchases are for the 6 Plus compared to 38% for the iPhone 6. We have modeled a 2.5-to-1 ratio favoring the iPhone 6, so a tilt toward the 6 Plus would be positive for Apple's phone ASPs and earnings. Demand in China is surprisingly high with 29% indicating they are very likely to choose the iPhone 6, more than other regions. Almost one-third of interested iPhone buyers currently own Samsung phones, foreshadowing significant share gain for Apple Inc. (NASDAQ:AAPL)."Click here for a free comprehensive Trend Analysis ReportComputer company Oracle Corporation (NYSE:ORCL) has upgraded Oracle Solaris Studio, a solution which provides a software development environment for building enterprise applications for deployment on Oracle Solaris, Oracle Linux, and other Linux-based systems. Oracle Corporation (NYSE:ORCL) announced on Tuesday that it had launched Oracle Solaris Studio 12.4 which it said would enable developers to generate higher performing, reliable, and secure applications in record time.The latest release of Oracle's #1 C, C++ and Fortran development environment for Oracle systems includes enhanced software analysis tools to help developers optimize application performance and identify memory errors for improved application reliability. It also includes enhanced standards-based, high performance compilers with advanced optimization capabilities, resulting in the best application performance on Oracle's newest SPARC and x86 systems. Over the past 52 weeks, the company has traded between $33.22 and $43.19.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
